This HTML5 document contains 42 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n21http://linked.opendata.cz/resource/AHFS/
n9http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n7http://linked.opendata.cz/resource/drugbank/company/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00031/identifier/kegg-drug/
n4http://linked.opendata.cz/resource/drugbank/dosage/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00031/identifier/drugbank/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00031/identifier/national-drug-code-directory/
n17http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n18http://www.drugs.com/mtm/
n6http://linked.opendata.cz/resource/drugbank/patent/
n15http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n23http://linked.opendata.cz/resource/drugbank/medicinal-product/
n8http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n25http://linked.opendata.cz/resource/drugbank/drug/DB00031/identifier/genbank/
n3http://linked.opendata.cz/ontology/drugbank/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00031/identifier/uniprotkb/
n11http://www.rxlist.com/cgi/generic2/
n5http://linked.opendata.cz/resource/drugbank/property/
n28http://linked.opendata.cz/resource/drugbank/drug/DB00031/identifier/wikipedia/
xsdhhttp://www.w3.org/2001/XMLSchema#
n27http://linked.opendata.cz/resource/drugbank/drug/DB00031/identifier/pharmgkb/
n13http://linked.opendata.cz/resource/atc/
n12http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00031
rdf:type
n3:Drug
n3:description
Tissue plasminogen activator (tPA). Tenecteplase is a 527 amino acid glycoprotein developed by introducing the following modifications to the complementary DNA (cDNA) for natural human tPA: a substitution of threonine 103 with asparagine, and a substitution of asparagine 117 with glutamine, both within the kringle 1 domain, and a tetra-alanine substitution at amino acids 296-299 in the protease domain.
n3:dosage
n4:271B409A-363D-11E5-9242-09173F13E4C5 n4:271B409B-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Gurbel PA, Hayes K, Bliden KP, Yoho J, Tantry US: The platelet-related effects of tenecteplase versus alteplase versus reteplase. Blood Coagul Fibrinolysis. 2005 Jan;16(1):1-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15650539 # Melzer C, Richter C, Rogalla P, Borges AC, Theres H, Baumann G, Laule M: Tenecteplase for the treatment of massive and submassive pulmonary embolism. J Thromb Thrombolysis. 2004 Aug;18(1):47-50. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15744554 # Ohman EM, Van de Werf F, Antman EM, Califf RM, de Lemos JA, Gibson CM, Oliverio RL, Harrelson L, McCabe C, DiBattiste P, Braunwald E: Tenecteplase and tirofiban in ST-segment elevation acute myocardial infarction: results of a randomized trial. Am Heart J. 2005 Jul;150(1):79-88. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16084152 # De Luca G, Suryapranata H, Chiariello M: Tenecteplase followed by immediate angioplasty is more effective than tenecteplase alone for people with STEMI. Commentary. Evid Based Cardiovasc Med. 2005 Dec;9(4):284-7. Epub 2005 Nov 2. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16380055 # : Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet. 2006 Feb 18;367(9510):569-78. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16488800
n3:group
approved
n3:halfLife
1.9 hours (mammalian reticulocytes, in vitro) >20 hours (yeast, in vivo) >10 hours (Escherichia coli, in vivo)
n3:indication
For treatment of myocardial infarction and lysis of intracoronary emboli
owl:sameAs
n15:DB00031 n17:DB00031
dcterms:title
Tenecteplase
adms:identifier
n20:DB00031 n22:P00750 n24:50242-038-61 n25:L00153 n26:D06070 n27:PA164776757 n28:Tenecteplase
n3:mechanismOfAction
Tenecteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action.
n3:packager
n7:271B4098-363D-11E5-9242-09173F13E4C5 n7:271B4097-363D-11E5-9242-09173F13E4C5
n3:patent
n6:1341432 n6:2129660
n3:synonym
tPA t-plasminogen activator t- PA Tissue-type plasminogen activator precursor
n12:hasAHFSCode
n21:20-12-20
n8:hasConcept
n9:M0335155
foaf:page
n11:tenecteplase.htm n18:tenecteplase.html
n3:Molecular-Formula
n5:271B40A0-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B409F-363D-11E5-9242-09173F13E4C5
n12:hasATCCode
n13:B01AD11
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
191588-94-0
n3:category
n3:clearance
* 99 - 119 mL/min [acute myocardial infarction patients]
n3:containedIn
n23:271B4099-363D-11E5-9242-09173F13E4C5
n3:Hydrophobicity
n5:271B409D-363D-11E5-9242-09173F13E4C5
n3:Isoelectric-Point
n5:271B409E-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n5:271B409C-363D-11E5-9242-09173F13E4C5